Sunho Biologics Inc

02898

Company Profile

  • Business description

    Sunho Biologics Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development and commercialization of biologics for the treatment of cancers and autoimmune diseases. It has three Core Products, IAH0968, IAP0971, and IAE0972, all of which are developed in-house. IAH0968 is an antibody-dependent cell-mediated cytotoxicity (ADCC) enhanced monoclonal antibody (mAb), and the company has initiated Phase II clinical trials for biliary tract carcinoma (BTC) and colorectal cancer (CRC). IAP0971 and IAE0972 are both immunocytokines and It has completed Phase I clinical trials for advanced solid tumors including non-small cell lung cancer (NSCLC) and CRC.

  • Contact

    No. 198 Peninsula Middle Road, Dipu Street
    Room 302, Building 3
    Anji County
    Zhejiang Province
    Huzhou
    CHN

    http://www.sunho-bio.com.cn

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    128

Stocks News & Analysis

stocks

Earnings up but shares overvalued for ASX gold miner

Higher gold prices are making a difference to the bottom line but investors overly optimistic.
stocks

Alphabet: Anthropic deal and Gemini momentum stand to deliver; Fair Value up 27%

We see faster cloud growth and improved longer-term profitability for Alphabet.
stocks

Overvalued ASX mining giant

Solid start to 2026 but shares overvalued.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,351.904.90-0.05%
CAC 408,239.1813.550.16%
DAX 4024,308.7868.890.28%
Dow JONES (US)47,446.79239.670.51%
FTSE 1009,653.828.200.09%
HKSE26,433.70273.551.05%
NASDAQ23,609.01404.141.74%
Nikkei 22550,512.321,212.672.46%
NZX 50 Index13,391.5914.490.11%
S&P 5006,863.5371.841.06%
S&P/ASX 2009,055.602.20-0.02%
SSE Composite Index3,996.9446.631.18%

Market Movers